Words of Wisdom:

"you always are a winner, all you have to do is have fun" - Drqayyum1

China Anti-Prostatic Hyperplasia Drug Market Research Report & Forecast to 2013-2017

  • Date Submitted: 07/09/2014 01:08 AM
  • Flesch-Kincaid Score: 45.8 
  • Words: 627
  • Essay Grade: no grades
  • Report this Essay
The report “Research Report on Research Report on China’s Anti-Prostatic Hyperplasia (PH) Drug Market″ by China Research and Intelligence is now available at RnRMarketResearch.com.

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.

In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.

Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.

Buy a copy this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=78595.

In 2012, the market size of China’s hospital-use anti-PH drugs reached CNY 3.67 billion, increasing by 12.6% YOY.

Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China’s hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.

There are numerous anti-PH drug manufacturers in China. In 2011, the total market share of top 4 manufacturers of China’s hospital-use anti-PH drugs by market share was 71.22%, which was slightly lower than that in 2010; the total market share of top 8 manufacturers was over 83%, with the highly-concentrated market. Among it, Sino-US Hangzhou MSD Pharmaceutical Co., Ltd. ranked the top, accounting for over 30% of the market share in 2011. Its primary variety is Finasteride...


Express your owns thoughts and ideas on this essay by writing a grade and/or critique.

  1. No comments